25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

SYRS (Syros) Stock Analysis
Buy, Hold or Sell?

Let's analyze Syros together

I guess you are interested in Syros Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Syros’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Syros’s Price Targets

I'm going to help you getting a better view of Syros Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Syros Pharmaceuticals Inc

I send you an email if I find something interesting about Syros Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Syros (30 sec.)










1.2. What can you expect buying and holding a share of Syros? (30 sec.)

How much money do you get?

How much money do you get?
$5.95
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
$0.59
Expected worth in 1 year
$-16.10
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
$-10.74
Return On Investment
-42,973.0%

For what price can you sell your share?

Current Price per Share
$0.03
Expected price per share
$0.015 - $0.16
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Syros (5 min.)




Live pricePrice per Share (EOD)
$0.03
Intrinsic Value Per Share
$-50.07 - $-36.07
Total Value Per Share
$-49.48 - $-35.48

2.2. Growth of Syros (5 min.)




Is Syros growing?

Current yearPrevious yearGrowGrow %
How rich?$16.6m$127.7m-$111m-666.6%

How much money is Syros making?

Current yearPrevious yearGrowGrow %
Making money-$164.5m-$49.3m-$115.2m-70.0%
Net Profit Margin-1,656.3%-331.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Syros (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#548 / 908

Most Revenue
#296 / 908

Most Profit
#889 / 908

Most Efficient
#757 / 908
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Syros?

Welcome investor! Syros's management wants to use your money to grow the business. In return you get a share of Syros.

First you should know what it really means to hold a share of Syros. And how you can make/lose money.

Speculation

The Price per Share of Syros is $0.025. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Syros.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Syros, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.59. Based on the TTM, the Book Value Change Per Share is $-4.17 per quarter. Based on the YOY, the Book Value Change Per Share is $1.58 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $1.49 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Syros.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-5.81-23,240.2%-5.81-23,240.2%-3.53-14,110.4%-3.70-14,805.5%-2.66-10,654.1%
Usd Book Value Change Per Share-4.17-16,689.1%-4.17-16,689.1%1.586,338.3%-0.47-1,872.4%0.04175.5%
Usd Dividend Per Share1.495,945.8%1.495,945.8%0.000.0%0.301,206.9%0.15603.4%
Usd Total Gains Per Share-2.69-10,743.3%-2.69-10,743.3%1.586,338.3%-0.17-665.6%0.19778.9%
Usd Price Per Share7.79-7.79-3.59-6.48-5.99-
Price to Earnings Ratio-1.34--1.34--1.02--1.86--2.29-
Price-to-Total Gains Ratio-2.90--2.90-2.27-50.38-31.64-
Price to Book Ratio13.24-13.24-0.75-4.12-3.05-
Price-to-Total Gains Ratio-2.90--2.90-2.27-50.38-31.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.025
Number of shares40000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share1.490.30
Usd Book Value Change Per Share-4.17-0.47
Usd Total Gains Per Share-2.69-0.17
Gains per Quarter (40000 shares)-107,432.52-6,655.53
Gains per Year (40000 shares)-429,730.10-26,622.14
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1237833-667563-42974048275-74897-26632
2475666-1335126-85947096550-149794-53254
3713498-2002689-1289200144825-224691-79876
4951331-2670252-1718930193100-299588-106498
51189164-3337815-2148660241375-374485-133120
61426997-4005378-2578390289650-449383-159742
71664830-4672940-3008120337925-524280-186364
81902663-5340503-3437850386200-599177-212986
92140495-6008066-3867580434475-674074-239608
102378328-6675629-4297310482750-748971-266230

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.011.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%6.04.00.060.0%7.04.00.063.6%
Dividend per Share1.00.00.0100.0%1.00.02.033.3%3.00.02.060.0%3.00.07.030.0%3.00.08.027.3%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%6.04.00.060.0%7.04.00.063.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Syros Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---4.172-4.1720%1.585-363%-0.468-89%0.044-9610%
Book Value Per Share--0.5880.5880%4.760-88%2.970-80%2.673-78%
Current Ratio--3.9523.9520%6.868-42%5.253-25%9.924-60%
Debt To Asset Ratio--0.9010.9010%0.478+89%0.592+52%0.375+140%
Debt To Equity Ratio--9.0939.0930%0.914+895%2.681+239%1.440+532%
Dividend Per Share--1.4861.4860%-+100%0.302+393%0.151+885%
Enterprise Value--208671818.410208671818.4100%181882675.000+15%211826928.682-1%249901386.676-16%
Eps---5.810-5.8100%-3.528-39%-3.701-36%-2.664-54%
Ev To Ebitda Ratio---1.327-1.3270%-2.077+56%-2.414+82%-3.785+185%
Ev To Sales Ratio--21.00221.0020%12.223+72%32.996-36%227.818-91%
Free Cash Flow Per Share---3.883-3.8830%-4.633+19%-3.450-11%-2.345-40%
Free Cash Flow To Equity Per Share---2.348-2.3480%0.251-1035%-0.083-96%0.314-847%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---36.068--------
Intrinsic Value_10Y_min---50.072--------
Intrinsic Value_1Y_max---2.625--------
Intrinsic Value_1Y_min---4.369--------
Intrinsic Value_3Y_max---8.641--------
Intrinsic Value_3Y_min---13.765--------
Intrinsic Value_5Y_max---15.566--------
Intrinsic Value_5Y_min---23.792--------
Market Cap670812.500-32794%220657818.410220657818.4100%96328675.000+129%176201128.682+25%161782609.341+36%
Net Profit Margin---16.563-16.5630%-3.313-80%-13.495-19%-39.158+136%
Operating Margin---16.047-16.0470%-6.083-62%-13.832-14%-39.458+146%
Operating Ratio--14.20914.2090%9.692+47%15.162-6%60.568-77%
Pb Ratio0.043-31060%13.24313.2430%0.754+1656%4.116+222%3.053+334%
Pe Ratio-0.004+100%-1.341-1.3410%-1.018-24%-1.858+39%-2.287+71%
Price Per Share0.025-31060%7.7907.7900%3.590+117%6.480+20%5.986+30%
Price To Free Cash Flow Ratio-0.006+100%-2.006-2.0060%-0.775-61%-2.198+10%-2.792+39%
Price To Total Gains Ratio-0.009+100%-2.900-2.9000%2.266-228%50.384-106%31.639-109%
Quick Ratio--3.8043.8040%7.760-51%6.007-37%13.470-72%
Return On Assets---0.979-0.9790%-0.202-79%-0.516-47%-0.528-46%
Return On Equity---9.877-9.8770%-0.386-96%-2.645-73%-1.654-83%
Total Gains Per Share---2.686-2.6860%1.585-269%-0.166-94%0.195-1479%
Usd Book Value--16662000.00016662000.0000%127736000.000-87%79870600.000-79%71815500.000-77%
Usd Book Value Change Per Share---4.172-4.1720%1.585-363%-0.468-89%0.044-9610%
Usd Book Value Per Share--0.5880.5880%4.760-88%2.970-80%2.673-78%
Usd Dividend Per Share--1.4861.4860%-+100%0.302+393%0.151+885%
Usd Enterprise Value--208671818.410208671818.4100%181882675.000+15%211826928.682-1%249901386.676-16%
Usd Eps---5.810-5.8100%-3.528-39%-3.701-36%-2.664-54%
Usd Free Cash Flow---109979000.000-109979000.0000%-124306000.000+13%-93732200.000-15%-63514400.000-42%
Usd Free Cash Flow Per Share---3.883-3.8830%-4.633+19%-3.450-11%-2.345-40%
Usd Free Cash Flow To Equity Per Share---2.348-2.3480%0.251-1035%-0.083-96%0.314-847%
Usd Market Cap670812.500-32794%220657818.410220657818.4100%96328675.000+129%176201128.682+25%161782609.341+36%
Usd Price Per Share0.025-31060%7.7907.7900%3.590+117%6.480+20%5.986+30%
Usd Profit---164574000.000-164574000.0000%-49301000.000-70%-93121600.000-43%-67288900.000-59%
Usd Revenue--9936000.0009936000.0000%14880000.000-33%13075800.000-24%6916400.000+44%
Usd Total Gains Per Share---2.686-2.6860%1.585-269%-0.166-94%0.195-1479%
 EOD+3 -5MRQTTM+0 -0YOY+14 -255Y+7 -3210Y+10 -29

3.3 Fundamental Score

Let's check the fundamental score of Syros Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.004
Price to Book Ratio (EOD)Between0-10.043
Net Profit Margin (MRQ)Greater than0-16.563
Operating Margin (MRQ)Greater than0-16.047
Quick Ratio (MRQ)Greater than13.804
Current Ratio (MRQ)Greater than13.952
Debt to Asset Ratio (MRQ)Less than10.901
Debt to Equity Ratio (MRQ)Less than19.093
Return on Equity (MRQ)Greater than0.15-9.877
Return on Assets (MRQ)Greater than0.05-0.979
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Syros Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.024
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-04-15 12:13:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Syros earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Syros to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -1,656.3%Β means thatΒ $-16.56 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Syros Pharmaceuticals Inc:

  • The MRQ is -1,656.3%. The company is making a huge loss. -2
  • The TTM is -1,656.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,656.3%TTM-1,656.3%0.0%
TTM-1,656.3%YOY-331.3%-1,325.0%
TTM-1,656.3%5Y-1,349.5%-306.8%
5Y-1,349.5%10Y-3,915.8%+2,566.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,656.3%-100.3%-1,556.0%
TTM-1,656.3%-188.1%-1,468.2%
YOY-331.3%-200.1%-131.2%
5Y-1,349.5%-393.6%-955.9%
10Y-3,915.8%-501.9%-3,413.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Syros is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Syros to theΒ Biotechnology industry mean.
  • -97.9% Return on Assets means thatΒ Syros generatedΒ $-0.98 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Syros Pharmaceuticals Inc:

  • The MRQ is -97.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -97.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-97.9%TTM-97.9%0.0%
TTM-97.9%YOY-20.2%-77.7%
TTM-97.9%5Y-51.6%-46.3%
5Y-51.6%10Y-52.8%+1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-97.9%-12.5%-85.4%
TTM-97.9%-12.3%-85.6%
YOY-20.2%-12.5%-7.7%
5Y-51.6%-13.8%-37.8%
10Y-52.8%-15.7%-37.1%
4.3.1.3. Return on Equity

Shows how efficient Syros is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Syros to theΒ Biotechnology industry mean.
  • -987.7% Return on Equity means Syros generated $-9.88Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Syros Pharmaceuticals Inc:

  • The MRQ is -987.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -987.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-987.7%TTM-987.7%0.0%
TTM-987.7%YOY-38.6%-949.1%
TTM-987.7%5Y-264.5%-723.2%
5Y-264.5%10Y-165.4%-99.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-987.7%-16.1%-971.6%
TTM-987.7%-16.2%-971.5%
YOY-38.6%-16.1%-22.5%
5Y-264.5%-21.0%-243.5%
10Y-165.4%-22.2%-143.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Syros Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Syros is operatingΒ .

  • Measures how much profit Syros makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Syros to theΒ Biotechnology industry mean.
  • An Operating Margin of -1,604.7%Β means the company generated $-16.05 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Syros Pharmaceuticals Inc:

  • The MRQ is -1,604.7%. The company is operating very inefficient. -2
  • The TTM is -1,604.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,604.7%TTM-1,604.7%0.0%
TTM-1,604.7%YOY-608.3%-996.4%
TTM-1,604.7%5Y-1,383.2%-221.5%
5Y-1,383.2%10Y-3,945.8%+2,562.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,604.7%-193.7%-1,411.0%
TTM-1,604.7%-286.4%-1,318.3%
YOY-608.3%-223.4%-384.9%
5Y-1,383.2%-393.8%-989.4%
10Y-3,945.8%-475.0%-3,470.8%
4.3.2.2. Operating Ratio

Measures how efficient Syros is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 14.21 means that the operating costs are $14.21 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Syros Pharmaceuticals Inc:

  • The MRQ is 14.209. The company is inefficient in keeping operating costs low. -1
  • The TTM is 14.209. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ14.209TTM14.2090.000
TTM14.209YOY9.692+4.517
TTM14.2095Y15.162-0.953
5Y15.16210Y60.568-45.407
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.2092.208+12.001
TTM14.2093.152+11.057
YOY9.6923.121+6.571
5Y15.1625.168+9.994
10Y60.5686.512+54.056
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Syros Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Syros is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 3.95Β means the company has $3.95 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Syros Pharmaceuticals Inc:

  • The MRQ is 3.952. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.952. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.952TTM3.9520.000
TTM3.952YOY6.868-2.916
TTM3.9525Y5.253-1.300
5Y5.25310Y9.924-4.672
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9523.726+0.226
TTM3.9523.930+0.022
YOY6.8684.316+2.552
5Y5.2535.777-0.524
10Y9.9246.144+3.780
4.4.3.2. Quick Ratio

Measures if Syros is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Syros to theΒ Biotechnology industry mean.
  • A Quick Ratio of 3.80Β means the company can pay off $3.80 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Syros Pharmaceuticals Inc:

  • The MRQ is 3.804. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.804. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.804TTM3.8040.000
TTM3.804YOY7.760-3.956
TTM3.8045Y6.007-2.203
5Y6.00710Y13.470-7.463
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8042.944+0.860
TTM3.8043.417+0.387
YOY7.7604.212+3.548
5Y6.0075.714+0.293
10Y13.4706.434+7.036
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Syros Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of SyrosΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Syros to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.90Β means that Syros assets areΒ financed with 90.1% credit (debt) and the remaining percentage (100% - 90.1%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Syros Pharmaceuticals Inc:

  • The MRQ is 0.901. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.901. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.901TTM0.9010.000
TTM0.901YOY0.478+0.423
TTM0.9015Y0.592+0.309
5Y0.59210Y0.375+0.217
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9010.342+0.559
TTM0.9010.343+0.558
YOY0.4780.330+0.148
5Y0.5920.362+0.230
10Y0.3750.387-0.012
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Syros is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Syros to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 909.3% means that company has $9.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Syros Pharmaceuticals Inc:

  • The MRQ is 9.093. The company is unable to pay all its debts with equity. -1
  • The TTM is 9.093. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ9.093TTM9.0930.000
TTM9.093YOY0.914+8.179
TTM9.0935Y2.681+6.413
5Y2.68110Y1.440+1.241
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.0930.402+8.691
TTM9.0930.421+8.672
YOY0.9140.396+0.518
5Y2.6810.446+2.235
10Y1.4400.486+0.954
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Syros generates.

  • Above 15 is considered overpriced butΒ always compareΒ Syros to theΒ Biotechnology industry mean.
  • A PE ratio of -1.34 means the investor is paying $-1.34Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Syros Pharmaceuticals Inc:

  • The EOD is -0.004. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.341. Based on the earnings, the company is expensive. -2
  • The TTM is -1.341. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.004MRQ-1.341+1.336
MRQ-1.341TTM-1.3410.000
TTM-1.341YOY-1.018-0.323
TTM-1.3415Y-1.858+0.517
5Y-1.85810Y-2.287+0.429
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.004-1.758+1.754
MRQ-1.341-2.592+1.251
TTM-1.341-3.216+1.875
YOY-1.018-3.278+2.260
5Y-1.858-6.457+4.599
10Y-2.287-7.176+4.889
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Syros Pharmaceuticals Inc:

  • The EOD is -0.006. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.006. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.006. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.006MRQ-2.006+2.000
MRQ-2.006TTM-2.0060.000
TTM-2.006YOY-0.775-1.231
TTM-2.0065Y-2.198+0.191
5Y-2.19810Y-2.792+0.594
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.006-2.331+2.325
MRQ-2.006-3.585+1.579
TTM-2.006-4.034+2.028
YOY-0.775-4.487+3.712
5Y-2.198-8.803+6.605
10Y-2.792-9.972+7.180
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Syros is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 13.24 means the investor is paying $13.24Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Syros Pharmaceuticals Inc:

  • The EOD is 0.043. Based on the equity, the company is cheap. +2
  • The MRQ is 13.243. Based on the equity, the company is expensive. -2
  • The TTM is 13.243. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.043MRQ13.243-13.201
MRQ13.243TTM13.2430.000
TTM13.243YOY0.754+12.489
TTM13.2435Y4.116+9.127
5Y4.11610Y3.053+1.063
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0431.585-1.542
MRQ13.2432.265+10.978
TTM13.2432.441+10.802
YOY0.7542.512-1.758
5Y4.1163.773+0.343
10Y3.0534.294-1.241
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Syros Pharmaceuticals Inc.

4.8.1. Institutions holding Syros Pharmaceuticals Inc

Institutions are holding 33.958% of the shares of Syros Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31Bain Capital Life Sciences Investors, LLC10.24930.0743275015100
2024-12-31BlackRock Inc1.03330277253156745.9921
2024-12-31Vanguard Group Inc0.99940268154-685159-71.8714
2024-12-31Omega Fund Management LLC0.93640.047925127000
2024-12-31Geode Capital Management, LLC0.73140196252-8443-4.1247
2024-12-31Affinity Asset Advisors, LLC0.5590.00461500001500000
2024-12-31Citigroup Inc0.5189013922413853720165.5022
2024-12-31Qube Research & Technologies0.455301221744445857.2057
2024-12-31TWO SIGMA SECURITIES, LLC0.40150.00331077421077420
2024-12-31Renaissance Technologies Corp0.3579096042-393-0.4075
2024-12-31HRT FINANCIAL LLC0.32620.000187535875350
2024-12-31XTX Topco Ltd0.30360.00158146052626182.5137
2024-12-31State Street Corp0.258806943000
2024-12-31Jane Street Group LLC0.1972052920529200
2024-12-31Two Sigma Investments LLC0.18210488612038671.5926
2024-12-31UBS Group AG0.167904505028322169.3089
2024-12-31Northern Trust Corp0.152104081200
2024-12-311492 Capital Management, LLC0.14630.00433924400
2024-12-31Virtu Financial LLC0.12220.0004327911316267.0538
2024-12-31Baader Bank INC0.08230.000322092220920
Total 18.18110.13674878457+39459+0.8%

4.9.2. Funds holding Syros Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-01-31Vanguard Institutional Extnd Mkt Idx Tr0.9602025763500
2025-01-31Fidelity Extended Market Index0.3638097607-1064-1.0783
2025-02-28iShares Micro-Cap ETF0.17080.00074583100
2024-12-31Extended Equity Market Fund K0.16680.000144745-616-1.358
2025-01-31Fidelity Total Market Index0.148403983100
2025-01-31Fidelity Series Total Market Index0.088402373000
2024-12-31Northern Trust Extended Eq Market Idx0.08420.00012260400
2024-12-31NT Ext Equity Mkt Idx Fd - L0.08420.00012260400
2024-12-31NT Ext Equity Mkt Idx Fd - NL0.06270.00011681400
2024-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04970.000113327-220-1.624
2025-01-31Spartan Total Market Index Pool E0.044301189400
2025-01-31Vanguard U.S. Eq Idx Β£ Acc0.039201051900
2025-01-31Fidelity Nasdaq Composite Index0.02730733200
2025-02-28State St US Extended Mkt Indx NL Cl C0.02550.0001683300
2024-12-31Extended Equity Market Fund M0.02170.00015812560.9729
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.02010.0001538653860
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.02010.0001538653860
2025-01-311290 VT Micro Cap K0.0180.0005484000
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.0130.0007348860.1723
2024-06-30SSgA U.S. Total Market Index Strategy0.01040.000328032101299.2877
Total 2.41880.0031649021+11035+1.7%

5.3. Insider Transactions

Insiders are holding 0.758% of the shares of Syros Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-12-02Nancy A SimonianSELL370700.27
2024-11-25Nancy A SimonianSELL1347130.27
2024-09-12Jason HaasBUY453441.68
2024-09-10Conley CheeBUY500001.51
2024-09-10Jason HaasBUY353631.55
2024-06-28Richard A YoungSELL348375.12
2024-04-02David RothSELL1504.98
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets168,174
Total Liabilities151,512
Total Stockholder Equity16,662
 As reported
Total Liabilities 151,512
Total Stockholder Equity+ 16,662
Total Assets = 168,174

Assets

Total Assets168,174
Total Current Assets144,980
Long-term Assets23,194
Total Current Assets
Cash And Cash Equivalents 139,526
Other Current Assets 5,454
Total Current Assets  (as reported)144,980
Total Current Assets  (calculated)144,980
+/-0
Long-term Assets
Property Plant Equipment 19,483
Long-term Assets Other 3,711
Long-term Assets  (as reported)23,194
Long-term Assets  (calculated)23,194
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities36,681
Long-term Liabilities114,831
Total Stockholder Equity16,662
Total Current Liabilities
Short-term Debt 8,991
Short Long Term Debt 6,667
Accounts payable 11,544
Other Current Liabilities 16,146
Total Current Liabilities  (as reported)36,681
Total Current Liabilities  (calculated)43,348
+/- 6,667
Long-term Liabilities
Long term Debt 34,556
Capital Lease Obligations 20,852
Long-term Liabilities Other 61,747
Long-term Liabilities  (as reported)114,831
Long-term Liabilities  (calculated)117,155
+/- 2,324
Total Stockholder Equity
Common Stock26
Retained Earnings -722,807
Other Stockholders Equity 739,443
Total Stockholder Equity (as reported)16,662
Total Stockholder Equity (calculated)16,662
+/-0
Other
Capital Stock26
Cash and Short Term Investments 139,526
Common Stock Shares Outstanding 28,326
Liabilities and Stockholders Equity 168,174
Net Debt -77,451
Net Invested Capital 57,885
Net Working Capital 108,299
Property Plant and Equipment Gross 27,117
Short Long Term Debt Total 62,075



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
> Total Assets 
4,921
61,494
43,631
91,323
78,488
106,766
149,978
213,250
182,935
244,486
168,174
168,174244,486182,935213,250149,978106,76678,48891,32343,63161,4944,921
   > Total Current Assets 
3,913
60,543
36,449
85,508
73,159
101,734
114,513
178,557
136,585
211,392
144,980
144,980211,392136,585178,557114,513101,73473,15985,50836,44960,5433,913
       Cash And Cash Equivalents 
3,801
60,393
35,909
58,588
32,205
49,886
41,441
173,984
92,302
167,467
139,526
139,526167,46792,302173,98441,44149,88632,20558,58835,90960,3933,801
       Short-term Investments 
0
25,005
25,005
25,005
39,844
49,793
49,975
0
38,067
34,837
0
034,83738,067049,97549,79339,84425,00525,00525,0050
       Net Receivables 
0
867
0
867
0
0
20,158
2,331
2,979
1,694
0
01,6942,9792,33120,1580086708670
       Other Current Assets 
112
150
540
2,096
1,110
2,055
2,939
2,242
3,237
7,394
5,454
5,4547,3943,2372,2422,9392,0551,1102,096540150112
   > Long-term Assets 
1,008
951
7,182
5,815
5,329
5,032
35,465
34,693
46,350
33,094
23,194
23,19433,09446,35034,69335,4655,0325,3295,8157,1829511,008
       Property Plant Equipment 
938
881
4,799
4,850
3,938
3,861
31,889
29,641
27,285
24,660
19,483
19,48324,66027,28529,64131,8893,8613,9384,8504,799881938
       Long Term Investments 
0
0
0
0
0
0
0
0
13,038
0
0
0013,03800000000
       Long-term Assets Other 
70
70
1,900
482
1,101
881
490
1,966
6,027
5,348
3,711
3,7115,3486,0271,9664908811,1014821,9007070
> Total Liabilities 
910
1,253
9,582
10,721
13,164
28,180
70,794
122,697
97,717
116,750
151,512
151,512116,75097,717122,69770,79428,18013,16410,7219,5821,253910
   > Total Current Liabilities 
910
1,252
7,956
9,567
12,413
19,529
23,516
28,624
31,508
30,778
36,681
36,68130,77831,50828,62423,51619,52912,4139,5677,9561,252910
       Short-term Debt 
0
133
133
336
94
18
2,556
3,456
4,022
4,142
8,991
8,9914,1424,0223,4562,55618943361331330
       Short Long Term Debt 
0
133
339
221
53
0
0
0
0
0
6,667
6,66700000532213391330
       Accounts payable 
594
928
5,035
2,415
2,283
3,309
5,853
3,603
3,692
6,411
11,544
11,5446,4113,6923,6035,8533,3092,2832,4155,035928594
       Other Current Liabilities 
316
324
2,788
6,266
10,036
14,276
9,368
9,356
13,613
15,895
16,146
16,14615,89513,6139,3569,36814,27610,0366,2662,788324316
   > Long-term Liabilities 
0
1
1,626
1,154
751
8,651
47,278
94,073
66,209
85,972
114,831
114,83185,97266,20994,07347,2788,6517511,1541,62610
       Long term Debt Total 
0
0
206
53
6
22
621
39,551
0
40,649
0
040,649039,5516212265320600
       Other Liabilities 
0
1
1,420
1,101
745
8,629
22,639
29,588
3,029
24,472
0
024,4723,02929,58822,6398,6297451,1011,42010
       Deferred Long Term Liability 
0
1,420
1,900
1,101
745
353
1,629
0
0
0
0
00001,6293537451,1011,9001,4200
> Total Stockholder Equity
3,973
60,241
34,049
80,602
65,324
78,586
79,184
90,553
85,218
127,736
16,662
16,662127,73685,21890,55379,18478,58665,32480,60234,04960,2413,973
   Common Stock
5
1
2
23
26
34
43
56
61
20
26
2620615643342623215
   Retained Earnings Total Equity0-558,2330-377,021-292,983-217,545-155,266-101,256000
   Accumulated Other Comprehensive Income 
0
-428
-931
-9
-42
-3
24
0
-79
102
0
0102-79024-3-42-9-931-4280
   Capital Surplus 
0
0
5,547
181,844
220,606
296,100
372,100
467,518
0
685,847
0
0685,8470467,518372,100296,100220,606181,8445,54700
   Treasury Stock00000000000
   Other Stockholders Equity 
966
1,922
5,547
181,844
220,606
296,100
372,100
467,518
548,815
685,847
739,443
739,443685,847548,815467,518372,100296,100220,606181,8445,5471,922966



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue9,936
Cost of Revenue-2,252
Gross Profit7,6847,684
 
Operating Income (+$)
Gross Profit7,684
Operating Expense-138,924
Operating Income-128,988-131,240
 
Operating Expense (+$)
Research Development108,153
Selling General Administrative28,282
Selling And Marketing Expenses0
Operating Expense138,924136,435
 
Net Interest Income (+$)
Interest Income6,816
Interest Expense-5,127
Other Finance Cost-0
Net Interest Income1,689
 
Pretax Income (+$)
Operating Income-128,988
Net Interest Income1,689
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-164,574-93,402
EBIT - interestExpense = -164,574
-162,490
-159,447
Interest Expense5,127
Earnings Before Interest and Taxes (EBIT)-159,447-159,447
Earnings Before Interest and Taxes (EBITDA)-157,195
 
After tax Income (+$)
Income Before Tax-164,574
Tax Provision-0
Net Income From Continuing Ops-164,574-164,574
Net Income-164,574
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses138,924
Total Other Income/Expenses Net-35,586-1,689
 

Technical Analysis of Syros
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Syros. The general trend of Syros is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Syros's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Syros Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Syros Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.031 < 0.0653 < 0.16.

The bearish price targets are: 0.015.

Know someone who trades $SYRS? Share this with them.πŸ‘‡

Syros Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Syros Pharmaceuticals Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Syros Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartSyros Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Syros Pharmaceuticals Inc. The current adx is .

Syros Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartSyros Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily Stochastic Oscillator ChartSyros Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartSyros Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartSyros Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily Williams %R ChartSyros Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily Average True Range (ATR) ChartSyros Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartSyros Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartSyros Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Syros Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-31STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-30STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-21ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Syros Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Syros Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.024
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Syros with someone you think should read this too:
  • Are you bullish or bearish on Syros? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Syros? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Syros Pharmaceuticals Inc

I send you an email if I find something interesting about Syros Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Syros Pharmaceuticals Inc.

Receive notifications about Syros Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.